Life Science: What Should We Be Prepared For In 2023 (Podcast)

W
Wavestone

Contributor

Wavestone
For the first time in 2023: Hello, and welcome to Second Opinion, the podcast of PEN Partnership, a Wavestone company.
UK Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

For the first time in 2023: Hello, and welcome to Second Opinion, the podcast ofPEN Partnership, a Wavestone company!

Join us as we kick off the year with a deep dive into two themes which will define pharma in coming year: Patient Individuality, and the Data Explosion.

More than just buzzwords and headlines, Shrinivas Anikhindi has sat down with two tenured pharma advisers atPEN Partnership, a Wavestone company, Jalilah Gibson and Nick Reynolds to dig into exactly what these themes mean, why they're so important, and what everyone should be doing to embrace them.

Over the course of a half-hour podcast, we run through:

  • Why patient-centricity and data literacy are relevant to each other despite seeming like opposites
  • How turning segmentation up, not down, can deliver the same benefits but far mor efficiently
  • Why data is a distraction when we should be looking at infrastructure and capability instead

The PEN Perspective Podcast · More Data, Fewer Patients: Life Sciences Trends in 2023

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More